Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
DAF Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, IF, E |
|---|---|
| Primary Accession | P08174 |
| Other Accession | NP_001108224, 168693643 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | Predicted: 48 kDa Observed: 49 kDa |
| Application Notes | DAF body can be used for detection of DAF by Western blot at 1 - 2 µg/ml. Antibody can also be used for Immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL. |
| Gene ID | 1604 |
|---|---|
| Target/Specificity | CD55; DAF antibody is human specific. At least two isoforms of DAF are known to exist; this antibody will only detect the longest isoform. |
| Reconstitution & Storage | DAF antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. |
| Precautions | DAF Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | CD55 |
|---|---|
| Synonyms | CR, DAF |
| Function | This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade (PubMed:7525274). Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage (PubMed:28657829). |
| Cellular Location | [Isoform 1]: Cell membrane; Single-pass type I membrane protein [Isoform 3]: Secreted [Isoform 5]: Secreted [Isoform 7]: Cell membrane; Lipid-anchor, GPI-anchor |
| Tissue Location | Expressed on the plasma membranes of all cell types that are in intimate contact with plasma complement proteins. It is also found on the surfaces of epithelial cells lining extracellular compartments, and variants of the molecule are present in body fluids and in extracellular matrix |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The decay-accelerating factor (DAF), also known as CD55, is an integral membrane glycoprotein that is involved in the regulation of the complement cascade (1). DAF limits excessive complement activation by accelerating their decay following DAF binding, thereby disrupting the cascade and preventing damage to host cells (2). Antigens present on the DAF glycoprotein constitute the Cromer blood group system (CROM) (3).
References
Nicholson-Weller A, March JP, Rosen CE, et al. Surface membrane expression by human blood leukocytes and platelts of decay-accelerating factor, a regulatory protein of the complement system. Blood 1985; 65:1237-44.
Seya T and Atkinson JP. Functional properties of membrane cofactor protein of complement. Biochem. J. 1989; 64:581-8.
Storry JR, Reid ME, and Yazer MH. The Cromer blood group system: a review. Immunohematology 2010; 109-18.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
